June 13, 2024: NCHR testified at the FDA listening session on Advisory Committee reform. We expressed concerns with the miscategorization of Consumer Representatives on AdComs and the ability of individuals with prior financial ties to industry to serve on these committees.
Read More »Author: Caroline Bradford
Advisory Committee Consumer Reps Often Fail To Represent Consumer Interests, Groups Tell US FDA
Pink Sheet, June 13, 2024: NCHR quoted from FDA listening session on optimizing the advisory committee process.
Read More »The Patient, Consumer, and Public Health Coalition Testified at an FDA Listening Session on Advisory Committees
June 13, 2024: The Patient, Consumer, and Public Health coalition testified at the FDA listening session on Advisory Committee reform. We expressed concerns with the miscategorization of Consumer Representatives on AdComs, the inherent conflicts of interests of committee members, and inadequate training provided to appointees.
Read More »NCHR’s Public Comment on Early Alzheimer’s Disease: Developing Drugs for Treatment; Draft Guidance for Industry
June 10, 2024: NCHR disagrees with assumptions made in FDA guidance aimed at developing drugs for treatment of early stages of Alzheimer’s dementia.
Read More »Readers respond to mothers in treatment for opioid use disorder, pandemic models, and more
STAT, June 8, 2024: Our Letter to the Editor at STAT News disagreed with the first Opinion commentary urging more use of antipsychotics for dementia patients. We explain that these drugs too often kill older patients or serve as chemical straight jackets,
Read More »